Twitter Beğeni Hilesi

#BigPharma is back at it. According to data from Patients For Affordable Drugs, brand name drug companies increased prices on 195 prescription drugs between June 30th and July 5th – faster than the rate of inflation: mmm-online.com/home/channel/p…

Numerous price hikes = record breaking profits 💵 #BigPharma giants reported expectation-beating Q2 earnings fueled by egregious pricing practices and anti-competitive tactics that block competition. Get the numbers: csrxp.org/big-pharma-ear…

The number of drugs #BigPharma giants have hiked prices on this year: Pfizer Inc.: 100 GSK: 23 Merck: 21 Bristol Myers Squibb: 10 See more data:

#BigPharma has a long history of hiking pricing – oftentimes at rates above inflation, escalating the crisis of affordability for Americans who face financial uncertainty purchasing necessary medications. Read more on their latest price hikes: csrxp.org/csrxp-big-phar…

.@JNJnews and @novartis reported earnings for Q2 2024. The results? #BigPharma continues to exceed Wall Street’s expectations thanks to its business-as-usual approach to price-gouging patients. Read the full report: csrxp.org/big-pharma-ear…

#BigPharma games the U.S. patent system – enabling brand name drug companies to extend monopolies over their biggest money makers. Get the facts about how these companies block competition from more affordable alternatives, like #biosimilars: csrxp.org/resources/csrx…

A recent Forbes column explores how #BigPharma games the patent system to extend exclusivity and monopoly pricing in the U.S. Read more from @avik: forbes.com/sites/theapoth…

FACT: In January 2024, #BigPharma increased prices on more than 775 brand name prescription drugs, with the median price outpacing the rate of inflation at the time. Get the facts: csrxp.org/csrxp-big-phar…

For far too long, #BigPharma has used the false excuse that R&D costs justify out-of-control #RxDrug prices. Multiple studies show: Big Pharma’s price hikes have little to no connection with the cost of developing new medications. Get the facts: csrxp.org/innovation-rhe…

U.S. drug prices are out-of-control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. See our solutions: csrxp.org/solutions/?utm…

Product hopping and patent thicketing are two anti-competitive tactics from #BigPharma’s patent abuse playbook. Read more: csrxp.org/patent-abuse/?…

NEW: Eli Lilly and Company & Amgen 🧪🔬🧬 posted blockbuster earnings after hiking prices on more than 40 #RxDrugs earlier this year. Surprised? Neither are we. Get the latest:

New research shows #BigPharma’s egregious pricing on GLP-1 diabetes and weight loss drugs and multimillion-dollar gene therapies are set to increase employers' health care costs next year. Read more: csrxp.org/dose-of-realit…

.Eli Lilly and Company's lower prices for Zepbound for only some patients at only some doses will have a limited impact, leave prices high for most patients, and should remind everyone that #BigPharma sets prices, and can choose to lower those prices at any time. csrxp.org/csrxp-eli-lill…

.Eli Lilly and Company & Amgen 🧪🔬🧬 blew past Wall Street analyst expectations thanks to sales of egregiously priced brand name drugs. Learn more: csrxp.org/big-pharma-ear…

New reports from Business Group on Health & Aon find health care costs for employers are projected to rise next year. The culprit? #BigPharma’s egregious prices on GLP-1s and high-priced treatments. Get the facts: csrxp.org/dose-of-realit…

📖MUST READ📖 R Street Institute's Wayne Brough dives deep into #BigPharma’s patent abuse that keeps #RxDrug prices artificially high at the expense of patients and the U.S. healthcare system. Congress must crack down on Big Pharma’s anti-competitive practices:

Campaign for Sustainable Rx Pricing launching new 7-figure ad campaign pushing for patent reforms to lower drug prices --Senate passed one such bill unanimously in July axios.com/pro/health-car…

🚨CSRxP launched a campaign to highlight #BigPharma’s egregious pricing practices and patent abuse that are the root cause of high drug prices — and encourage lawmakers to pass bipartisan, market-based solutions to hold Big Pharma accountable. More:

CSRxP’s new campaign will support growing bipartisan momentum to crack down on #BigPharma’s rampant abuse of the patent system in order to lower #RxDrug prices for patients. Read more in Axios Pro: axios.com/pro/health-car…